I
mmune responses to vector-derived antigens or to the transgene product are a serious hurdle for gene replacement therapy. Upon in vivo gene transfer, signals derived from the procedure or from the presence of vector-associated molecular structures (such as viral particles) can cause activation of professional antigen-presenting cells. The ensuing adaptive immune response leads to production of neutralizing antibodies to the vector that abolish the ability to readminister. Antibodies to the transgene product may enhance clearance or interfere with the biological activity of the therapeutic protein. This issue is of particular concern in treatment of systemic protein deficiencies such as the X-linked bleeding diathesis hemophilia B, which is caused by mutations in the coagulation factor IX (F.IX) gene (1) . Equally important, activation of CD8 ϩ T cells can result in a cytotoxic T lymphocyte (CTL) response capable of eliminating cells that display transgene product-or vector-derived peptides on their surface. Antibody formation and efficient CTL responses typically depend on T help.
In general, the risk for immune responses is influenced by a number of factors, including the design of the vector, the target tissue, levels of gene expression, and genetic factors. Immune responses to the transgene product are more likely if a non-self protein is expressed (2) . Gene transfer to the liver with an earlygeneration adenoviral vector often results in high but transient levels of expression because of CTL-mediated elimination of hepatocytes (3, 4) . Transduced hepatocytes are killed mostly by Fas-Fas ligand-induced cell death mediated by CD8 ϩ T cells, which are part of a lymphocytic inflammatory infiltrate and are specific to the transgene product or to adenoviral proteins expressed from the vector backbone (5-7). Additionally, antibodies to the transgene product are produced that eliminate systemic expression (8, 9) . Adenoassociated viral (AAV) vectors have been more suitable for sustained transgene expression because of lower innate immunity, less efficient transduction of antigen-presenting cells, lack of viral coding sequences, and lower potential to cause inflammation (10) (11) (12) (13) . Nonetheless, cellular and humoral responses remain obstacles (14) (15) (16) .
Upon in vivo gene transfer, hepatocyte-restricted transgene expression has the capacity to provide therapeutic circulating levels while avoiding deleterious immune responses and, moreover, inducing immune tolerance to the transgene product (9, 10, (17) (18) (19) (20) (21) (22) (23) (24) . Tolerized animals fail to form antibodies to this neoantigen after subsequent attempts to immunize with protein formulated in adjuvant (23) (24) (25) . Deletion and anergy of CD4 ϩ T cells with receptor to the transgene product has been described (22) . Furthermore, activation of CD4 ϩ regulatory T cells (T reg ) capable of suppressing antibody formation after adoptive transfer has been documented (23) . The significance of this discovery and effects on cellular responses had been unknown.
This study demonstrates that gene transfer to the liver not only results in a lack of CTL responses but also actively prevents subsequent cytolytic responses to the transgene product and to viral antigens expressed in the liver through an in vivo suppression mechanism that is mediated by CD4 ϩ T reg (which had been activated by hepatic F.IX expression). Therefore, one should be able to develop protocols that abrogate undesired T cell responses to transduced cells by augmenting T reg responses to the transgene product.
Results

Sustained Expression After Secondary Gene Transfer with Adenoviral
Vector. These experiments were designed to test the hypothesis that animals tolerized to F.IX by hepatic gene transfer will continue to express the transgene after administration of a known activator of CTLs [an E1͞E3-deleted adenoviral vector, Ad-hF.IX, expressing human F.IX (hF.IX) from the CMV immediate-early enhancer͞promoter]. Male immune competent C3H͞HeJ (H-2 k ) and BALB͞c (H-2 d ) mice received portal vein injections of AAV-ApoE͞hAAT-hF.IX for expression of hF.IX from a hepatocyte-specific promoter [1 ϫ 10 11 vector genomes (vg) per mouse; n ϭ 4 per strain]. Two strains were used to eliminate strain-specific observations. In previous work we showed that hepatic gene transfer with this vector and dose directs sustained systemic expression of hF.IX in these strains at levels of up to 300 ng͞ml (note that hepatic AAV gene transfer in C3H and BALB͞c mice is less efficient compared with widely used C57BL͞6 mice) (23) .
All animals showed systemic hF.IX levels (50-300 ng͞ml) without evidence for anti-hF.IX IgG (Fig. 1 D-F and J-L) . Ageand sex-matched control mice (n ϭ 4 per strain) did not receive AAV gene transfer. As expected, hF.IX expression in plasma of these control mice was transient after i.v. injection of Ad-hF.IX (4 ϫ 10 10 particles per mouse) and became undetectable within 4 weeks (Fig. 1 A and G) . These mice formed high-titer IgG1 and IgG2a antibodies to hF.IX, indicating T helper 2-and T helper 1-dependent responses ( Fig. 1 
B, C, H, and I). No hF.IX expression was detectable in the liver when analyzed after 3-4 months (Fig. 2 E and K).
In contrast, mice expressing hF.IX from prior hepatic AAV gene transfer showed an increase in hF.IX plasma levels to, on average, 1-2 g͞ml, when Ad-hF.IX vector was injected 9-10 weeks after the initial AAV administration. These levels (20-40% of normal levels in a human) would be curative of the disease. Expression was sustained for the duration of the experiment ( In vitro CTL assays demonstrated cytolytic activity against hF.IXexpressing MHC class I-matched target cells using effector cells (splenocytes) from control mice injected with the Ad-hF.IX vector, but not using cells from mice tolerized to hF.IX by prior hepatic AAV gene transfer ( Fig. 3A; three independent experiments in C3H͞HeJ mice). Nonetheless, the latter animals had detectable cytolytic activity to target cells transduced with an Ad-LacZ vector, indicating activation of CTLs to adenoviral vector-derived antigens (Fig. 3B) . Analysis of genomic DNA by real-time PCR showed that livers of C3H͞HeJ mice with prior hepatic AAV gene transfer maintained more Ad-hF.IX genomes (0.81 Ϯ 0.28 copies per diploid genome at week 2 and 0.36 Ϯ 0.11 at 3 months) than control mice (0.55 Ϯ 0.13 at week 2 and 0.1 Ϯ 0.01 at 3 months; n ϭ 4 per group; data not shown). Compared with controls, mice tolerized to hF.IX had reduced frequencies of T cells reactive not only to hF.IX but also to adenoviral vector after injection of Ad-hF.IX, as determined by ELISpot assay ( Table 1) . Frequencies of IFN-␥-and IL-2-secreting cells in response to stimulation with adenoviral vector particles were 19-50% of those observed in controls.
Antigen Specificity and Requirements. In the next set of experiments, we challenged AAV-hF.IX-transduced C3H͞HeJ mice with Ad-LacZ vector and AAV-LacZ-transduced mice with Ad-hF.IX vector. AAV vector administration was again by portal vein infusion, and adenoviral vector was given 1.5 months later by tail vein injection. As expected, an additional cohort receiving AAV-hF.IX followed by Ad-hF.IX showed high levels of hF.IX expression with nearly undetectable levels of anti-hF.IX 1 month after adenoviral gene transfer (Fig. 4A) . Mice that were injected with AAV-hF.IX followed by Ad-LacZ continued to express hF.IX (50-100 ng͞ml) without anti-hF.IX formation (Fig. 4) . Consistent with CTL responses expected for this vector, hepatic expression of ␤-galactosidase became undetectable by 1 month (data not shown). Superinfected hepatocytes expressing both hF.IX (from AAV) and LacZ (from adenovirus vector) were detectable at weeks 1-2 but not subsequently, indicating that the immune response targeted all Ad-LacZ-transduced cells (data not shown). In the reverse experiment, AAV-LacZtransduced mice that subsequently received Ad-hF.IX vector lost hF.IX expression and developed antibodies to hF.IX within 1 month after Ad-hF.IX gene transfer (Fig. 4) . These results show that hepatic AAV gene transfer did not cause a general unresponsiveness of the immune system. Induction of immune tolerance to hF.IX antigen was required for sustained expression from an otherwise immunogenic adenoviral vector (expressing the same transgene). Introduction of an independent set of By using the identical vector administration protocol from antigens resulted in the expected loss of adenovirally transduced hepatocytes.
Regulatory CD4 ؉ T Cells Suppress Immune-Mediated Destruction of
Hepatocytes in Vivo. The fact that hF.IX expression from the Ad-hF.IX was sustained in tolerized mice despite T cell responses to adenovirus (detectable in vitro; Fig. 2B and Table 1 ) indicated an in vivo suppression mechanism. To test for activation of regulatory cells, splenocytes from C3H͞HeJ mice tolerized to hF.IX by hepatic AAV gene transfer were adoptively transferred to naïve mice of the same strain (Fig. 5A ). Controls were injected with cells from C3H͞HeJ mice that had not received gene transfer. On the following day all recipient mice were given an i.v. injection of Ad-hF.IX vector.
All recipients of CD4 ϩ splenocytes from tolerized mice showed prolonged hF.IX expression (n ϭ 4 per experimental group; Fig. 5 B and C) . At 2 months, systemic expression was, on average, 0.7 g͞ml (14% of normal human levels and therefore well in the therapeutic range), and 1-2% of hepatocytes (as determined by image analysis) stained positive for hF.IX (Fig. 6 A and B) . Mice that received CD4 ϩ cells from naïve controls without exception lost systemic and hepatic hF.IX expression by this time point (Figs. 5B and 6D ). Animals injected with CD4-depleted cells from tolerized mice expressed undetectable to low levels of hF.IX in the circulation by 2 months (Fig. 5C ) and had largely lost hF.IX expression in the liver (Fig. 6C; Ͻ0 .1% hF.IX-positive hepatocytes). Animals from both of these control groups, in contrast to those injected with CD4 ϩ cells from tolerized mice, developed higher-titer antibodies to hF.IX (Fig. 5D) . Livers of mice that had received CD4 ϩ cells from tolerized animals showed normal morphology and did not contain CD8 ϩ cells at 2 months (Fig. 6 E and G) , whereas livers from all other experimental groups had substantial inf lammation and hepatic injury (Fig.  6 H-J) . CD8 ϩ infiltrate was still detectable in some livers of mice that received control cells (Fig. 6F) . These data show that CD4 ϩ T reg suppressed humoral and inf lammatory immune responses to hF.IX and to Ad-hF.IX transduced hepatocytes.
We used flow cytometry to determine changes in the CD4 ϩ splenocyte population after gene transfer. There was an increase in CD4 ϩ lymphocytes of Ad-hF.IX transduced C3H͞HeJ mice compared to animals that had not been subjected to gene transfer. This rise was largely due to an increase in CD4 ϩ CD62L ϩ cells and was greater in tolerized animals (i.e., mice that had received prior AAV-hF.IX gene transfer; Fig. 7A ). This result indicates homing of CD4 ϩ T cells to this lymphoid organ. In all groups, Ϸ90% of CD4 ϩ CD62L ϩ cells were CD25 Ϫ (data not shown). Only CD4 ϩ splenocytes from tolerized mice showed a measurable (1.8-fold) increase in mRNA levels of the transcription factor FoxP3, which is expressed by naturally occurring CD4 ϩ T reg (Fig. 7C ). Such T reg constitutively express CD25 and glucocorticoid-induced TNF receptor (GITR) on the cell surface, and we indeed found a correlating increase in CD4 ϩ CD25 ϩ GITR ϩ splenocytes in tolerized mice (Fig. 7B ).
Discussion
Treatment of inherited protein deficiency by gene therapy may be limited by immune responses to the therapeutic transgene product, which may represent a neoantigen. Recent studies demonstrate induction of immune tolerance to the transgene product by restricting expression to hepatocytes (9, 10, (17) (18) (19) (20) 24) . Our study reveals an in vivo suppression mechanism that is mediated by CD4 ϩ T reg and that is capable of blocking the development of an inflammatory CD8 ϩ T cell response that otherwise leads to immune-mediated destruction of hepatocytes.
Tolerance induction to hF.IX by AAV-mediated hepatic gene transfer blocked subsequent activation of CTL responses to hF.IX and allowed for systemic administration of a viral vector that normally causes hepatocellular destruction. Earlier studies suggested that CTL responses to adenoviral vector-derived antigens were sufficient to eliminate transgene expression (7). However, our study demonstrates that it is possible to prevent at least adaptive immune responses to vg-encoded antigens by prior induction of tolerance to the transgene product. Because inflammatory signals derived from infection, injury, or repeat administration of viral vector can cause activation of T cells, it is important that hyporesponsiveness among cytolytic T cells is established. Despite the well documented immunogenicity of proteins expressed from the adenoviral genome (5), we achieved sustained increases in hF.IX expression levels upon secondary gene transfer with this vector.
Although we observed in vitro cytokine production and cytolytic activity to adenoviral antigens, this response did not cause T cell infiltrates in the liver or loss of transgene expression in vivo (''split tolerance''). These results pointed toward an in vivo suppression mechanism, which we have been able to confirm by adoptive transfer experiments. Transfer of CD4 ϩ cells, which contained hF.IX antigen-experienced cells (but which were naïve to adeno- Expression of the same transgene by both (AAV and adenoviral) vectors was important to achieve a sustained increase in expression while avoiding detrimental immune responses. The reduction in the frequency of T cells reactive to adenovirus may be explained by a ''bystander'' suppression-effect T reg with reactivity to hF.IX (26) . Alternatively, T cell responses to adenoviral antigens could have been amplified by the response to hF.IX in control animals. In tolerized mice, only transient hF.IX expression was observed in other tissues such as lung or spleen (data not shown) or if secondary adenoviral gene transfer was directed to skeletal muscle (unpublished observations). Thus, the liver likely has distinct properties with regard to antigen presentation or homing and function of T reg .
Recent clinical studies have shown that hepatic AAV-hF.IX gene transfer in human subjects with hemophilia B can be associated with loss of transgene expression due to a memory CD8 ϩ T cell response to AAV capsid (14) . Therefore, one has to caution that the activity of T reg may be less effective in the context of memory T cells to viral antigens that were originally generated by natural infection. Nonetheless, our current study provides proof-of-principle that the immune system has a mechanism in place that can be exploited to overcome CD8 ϩ T cell responses in gene transfer. CD4
ϩ T reg play a role in promoting sustained transgene expression by suppressing T cell responses to the transgene product and to viral antigens. Tolerance induction protocols to the transgene product that expand T reg may therefore hold the key to sustained therapeutic expression.
Methods
Viral Vectors. AAV vector expressing an hF.IX minigene from the apolipoprotein A enhancer linked to the human ␣ 1 -antitrypsin promoter (ApoE͞hAAT) was as described (23) . AAV (serotype 2) vector was produced by triple transfection of HEK-293 cells and purified by repeated CsCl centrifugation as published (27) . Vector titers were determined by quantitative slot blot hybridization. AAV2-LacZ vector for expression of ␤-galactosidase from the EF1␣ promoter was kindly provided by H. Nakai (University of Pittsburgh, Pittsburgh). E1͞E3-deleted adenoviral vector expressing hF.IX or ␤-galactosidase from the CMV immediate-early enhancer͞promoter was as described earlier (8, 28) . This vector was produced by infection of HEK-293 cells and purified by CsCl centrifugation by using standard protocols.
Animal Experiments. Male C3H͞HeJ and BALB͞c mice (4-6 weeks old) were purchased from The Jackson Laboratory. AAV vector (1 ϫ 10 11 vg per animal) was infused into the portal vein as described (29) . Adenoviral gene transfer (4 ϫ 10 10 particles per mouse) was through tail vein injection. Blood was collected 
